Who we are

Specialists in protease inhibitor design, and nucleoside- and nucleotide science. Medivir’s strategy is to apply our scientific expertise to the area of oncology to develop innovative anti-cancer drugs.

Medivir’s approach to cancer drug development

The wheel illustrates how our clinical- and early research projects align with the hallmarks of cancer.

To make our R&D portfolio even stronger

we continuously evaluate new oncology projects. Criteria assessed for a new project to be included:

  • Medical need
  • Competitive landscape
  • Commercial potential
  • Scientific- and financial feasibility of the development program